March 27, 2019

Bayer statement on jury's decision in phase two of California glyphosate trial

more

March 25, 2019

Bayer reaches settlement to resolve Xarelto™ litigation

more

March 19, 2019

Bayer statement on jury's decision in phase one of California glyphosate trial

more

March 08, 2019

Not intended for U.S. and UK Media

Bayer submits European marketing authorization application for darolutamide

more

March 05, 2019

Not intended for U.S. and UK Media

Bayer submits darolutamide for marketing authorization in Japan

more

February 27, 2019

Fiscal 2018:

Bayer increases sales and earnings - leader in agriculture after acquisition

more

February 27, 2019

Not intended for U.S. and UK Media

Bayer completes rolling submission for darolutamide in U.S.

more

February 26, 2019

Bayer proposes dividend for 2018 of 2.80 euros per share

more

February 15, 2019

Not intended for U.S. and UK Media

Bayer exercised option to obtain full licensing rights for larotrectinib and BAY 2731954 (LOXO-195)

more

February 14, 2019

Not intended for U.S. and UK Media - American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) 2019

Bayer's darolutamide plus androgen deprivation therapy (ADT) significantly extends metastasis-free survival with a favorable safety profile compared to placebo plus ADT in non-metastatic castration-resistant prostate cancer

more